Dale E Yelton from 2704 Gary Dr, Tulsa, OK 74114, Phone: 918 742-6048

Method For Inhibiting Immunoglobulin-Induced Toxicity Resulting From The Use Of Immunoglobulins In Therapy And In Vivo Diagnosis
view source
US Patent:

7247302, Jul 24, 2007
Filed:

Aug 1, 1997
Appl. No.:

08/905293
Inventors:

Mae Joanne Rosok - Seattle WA, US
Dale E. Yelton - Seattle WA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 39/40
A61K 39/395
A61K 49/00
US Classification:

4241331, 4241301, 4241741, 4241411, 4241421, 4241781, 424 92
Abstract:

The present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an immunoglobulin or Ig fusion protein molecule to the subject, the immunoglobulin molecule having a variable region and a constant region, the immunoglobulin molecule being modified prior to administration by inactivation of at least a portion of the constant region.

Mutant Br96 Antibodies Reactive With Human Carcinomas
view source
US Patent:

57288216, Mar 17, 1998
Filed:

Aug 4, 1994
Appl. No.:

8/285936
Inventors:

Dale Yelton - Seattle WA
Scott Glaser - San Diego CA
William Huse - Del Mar CA
Mae Joanne Rosok - Seattle WA
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07H 2104
C12P 2108
US Classification:

536 2353
Abstract:

The present invention provides mutant BR96 polypeptides (and nucleotide sequences encoding them) having a variable region comprising an amino acid sequence derived from the variable region of BR96.

Mutant Br96 Antibodies Reactive With Human Carcinomas
view source
US Patent:

57924562, Aug 11, 1998
Filed:

Jun 7, 1995
Appl. No.:

8/487860
Inventors:

Dale Yelton - Seattle WA
Scott Glaser - San Diego CA
William Huse - Del Mar CA
Mae Joanne Rosok - Seattle WA
Assignee:

Bristol-Myers Squibb Company - New York NY
International Classification:

A61K 39395
C12P 2108
US Classification:

4241331
Abstract:

The present invention provides mutant BR96 polypeptides having a variable region comprising an amino acid sequence derived from the variable region of BR96.